Literature DB >> 6130004

Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526.

D M Ackerman, A L Blumberg, J P McCafferty, S S Sherman, J Weinstock, C Kaiser, B Berkowitz.   

Abstract

SK&F 82526 and its enantiomers have been shown to increase renal blood flow and decrease renal vascular resistance in the anesthetized dog. The effect of the racemate on lowering systemic blood pressure in the anesthetized dog and the spontaneously hypertensive rat has been shown to be caused by the R-enantiomer with the S-enantiomer being devoid of significant activity on blood pressure. The mechanism by which the R-enantiomer decreases blood pressure is not systemic vasodilatation or prejunctional inhibition of norepinephrine release but appears to result from a unique stimulation of the postjunctional dopamine receptor. Racemic SK&F 82526 also has been shown to increase renal blood flow in an ischemic model of acute renal failure.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6130004

Source DB:  PubMed          Journal:  Fed Proc        ISSN： 0014-9446


  9 in total

1.  A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites.

Authors:  J A Ziemniak; V K Boppana; M J Cyronak; R M Stote
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

2.  Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension.

Authors:  M P Caruana; M Heber; G Brigden; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

3.  A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Proceedings of the British Pharmacological Society. University of Southampton, 17th-19th July 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

5.  Effects of cyclic AMP-affecting agents on contractile reactivity of isolated mesenteric and renal resistance arteries of the rat.

Authors:  B J Heesen; J G De Mey
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

6.  Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

7.  Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.

Authors:  R M Carey; R M Stote; J W Dubb; L H Townsend; C E Rose; D L Kaiser
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

9.  Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis.

Authors:  P Vlavianos; R J Polson; A Settin; J Glover; D Westaby; R Williams
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.